Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : National Eye Institute
Deal Size : $1.8 million
Deal Type : Funding
RevOpsis Wins $1.8M Grant for Ophthalmic Therapy R&D Advancement
Details : The SBIR grant will fund critical R&D activities, including multidose GMP toxicology studies in nonhuman primates for RO-104, a first-in-class fully human modular tri-specific biologic.
Product Name : RO-104
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 15, 2024
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : National Eye Institute
Deal Size : $1.8 million
Deal Type : Funding
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : $16.5 million
Deal Type : Funding
RevOpsis Secures Seed Funding for First-in-Class Tri-Specific Therapy for Neovascular AMD
Details : Through the funding, RevOpsis is well positioned to advance clinical development of RO-104, first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.
Product Name : RO-104
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 25, 2024
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : $16.5 million
Deal Type : Funding
Reset All
